TARA K GREGORY

Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology DENVER, CO NPI 1407973993

General Payments — all program years on this page

$80,669.09

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 213
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $1,754.44 across 18 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Consulting Fee $1,350.001
Food and Beverage $404.4417

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Janssen Biotech, Inc. $1,412.992
Celgene Corporation $91.654
ABBVIE INC. $76.624
SOBI, INC $47.262
Astellas Pharma US Inc $28.131
BeiGene USA, Inc. $23.261
Daiichi Sankyo Inc. $21.711
Legend Biotech USA Inc. $21.301
Genmab U.S., Inc. $17.421
Genentech USA, Inc. $14.101

By program year

Program yearAmountRecords
2018 $26,166.4659
2019 $38,883.6570
2020 $11,019.9015
2021 $66.533
2022 $2,090.1818
2023 $687.9330
2024 $1,754.4418

Records — PY2024 (18)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1078362214 Janssen Biotech, Inc. $62.99 09/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1078362405 Janssen Biotech, Inc. $1,350.00 11/01/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1089428307 Daiichi Sankyo Inc. $21.71 12/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1101124840 Celgene Corporation $20.80 01/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1101124846 Celgene Corporation $16.21 06/19/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1101124848 Celgene Corporation $22.84 09/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1101124854 Celgene Corporation $31.80 11/14/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1103837246 ABBVIE INC. $20.11 03/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1103837248 ABBVIE INC. $17.53 09/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1103837250 ABBVIE INC. $24.76 11/07/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1103837252 ABBVIE INC. $14.22 12/14/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1120859307 BeiGene USA, Inc. $23.26 12/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1126832745 Genmab U.S., Inc. $17.42 11/20/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1131691287 Legend Biotech USA Inc. $21.30 11/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1133122036 Genentech USA, Inc. $14.10 12/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139446214 Astellas Pharma US Inc $28.13 11/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1141428407 SOBI, INC $19.18 12/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1141439181 SOBI, INC $28.08 08/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.